亚虹医药-U
(688176)
| 流通市值：77.07亿 | | | 总市值：77.07亿 |
| 流通股本：5.72亿 | | | 总股本：5.72亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 155,353,308.79 | 71,085,894.94 | 277,121,519.19 | 216,408,302.14 |
| 营业收入 | 155,353,308.79 | 71,085,894.94 | 277,121,519.19 | 216,408,302.14 |
| 二、营业总成本 | 411,108,158.28 | 189,734,751.55 | 726,362,997.2 | 492,121,292.52 |
| 营业成本 | 40,008,209.75 | 19,504,870.05 | 71,961,143.25 | 54,631,550.03 |
| 税金及附加 | 546,855.37 | 112,711.7 | 2,050,495.09 | 1,755,068.12 |
| 销售费用 | 170,553,092.18 | 73,100,728.75 | 271,966,866.54 | 191,121,748.62 |
| 管理费用 | 42,162,950.82 | 19,716,939.79 | 93,356,533.88 | 69,000,691.72 |
| 研发费用 | 153,385,279.4 | 74,193,099.85 | 282,625,461.01 | 169,848,302.99 |
| 财务费用 | 4,451,770.76 | 3,106,401.41 | 4,402,497.43 | 5,763,931.04 |
| 其中:利息费用 | 5,243,816.18 | 2,622,165.67 | 8,272,203.69 | 9,441,526.3 |
| 其中:利息收入 | 2,016,690.13 | 1,389,544.96 | 7,686,674.19 | 5,954,756.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,035,445.43 | 4,551,202.98 | 6,822,715.63 | 5,001,887.04 |
| 加:投资收益 | 9,959,722.35 | 1,316,431.34 | 15,022,930.99 | 14,710,746.35 |
| 资产处置收益 | 46,782.14 | 54,516.47 | -610.68 | 307.4 |
| 资产减值损失(新) | -207,875.8 | -215,423.49 | -7,745.43 | 22,003.04 |
| 信用减值损失(新) | -1,919,577 | 364,475.11 | -4,131,976.87 | -4,987,773.47 |
| 其他收益 | 2,166,241.12 | 217,684.03 | 3,209,591.01 | 2,780,484.19 |
| 四、营业利润 | -242,674,111.25 | -112,359,970.17 | -428,326,573.36 | -258,185,335.83 |
| 加:营业外收入 | 66,281.28 | 80,732.52 | 88.5 | - |
| 减:营业外支出 | 2,163,000 | 2,104,986.77 | 5,079,052.23 | 3,458,461.82 |
| 五、利润总额 | -244,770,829.97 | -114,384,224.42 | -433,405,537.09 | -261,643,797.65 |
| 减:所得税费用 | 172,282.07 | 110,834.91 | -660,490.24 | -592,956.62 |
| 六、净利润 | -244,943,112.04 | -114,495,059.33 | -432,745,046.85 | -261,050,841.03 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -244,943,112.04 | -114,495,059.33 | -432,745,046.85 | -261,050,841.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -238,604,759.91 | -112,398,504.64 | -416,380,076.76 | -248,946,848.25 |
| 少数股东损益 | -6,338,352.13 | -2,096,554.69 | -16,364,970.09 | -12,103,992.78 |
| 扣除非经常损益后的净利润 | -250,930,825.16 | -116,215,668.66 | -435,137,568.35 | -266,860,469.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.42 | -0.2 | -0.74 | -0.44 |
| (二)稀释每股收益 | -0.42 | -0.2 | -0.74 | -0.43 |
| 八、其他综合收益 | -1,073,071.36 | 1,173,877.89 | -1,487,000.35 | 244,644.07 |
| 归属于母公司股东的其他综合收益 | -597,210.98 | 1,414,168.88 | -1,199,172.44 | 258,886.82 |
| 九、综合收益总额 | -246,016,183.4 | -113,321,181.44 | -434,232,047.2 | -260,806,196.96 |
| 归属于母公司股东的综合收益总额 | -239,201,970.89 | -110,984,335.76 | -417,579,249.2 | -248,687,961.43 |
| 归属于少数股东的综合收益总额 | -6,814,212.51 | -2,336,845.68 | -16,652,798 | -12,118,235.53 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-04-18 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |